Medicare ends automatic extra payments for FDA breakthrough devices

CMS has ended the automatic special Medicare payment pathway for FDA-designated breakthrough medical devices, a policy reversal that will slow reimbursement for novel technologies. The change affects device makers' revenue timelines and may dampen investment in high-risk innovation. Uncertainty remains over which devices will still qualify for expedited coverage.